BioMarin Pharmaceutical Inc. (BMRN)
NMS – Real vaqt narxi. Valyuta: USD
52.88
+0.30 (0.57%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Find any stock by ticker or company name

NMS – Real vaqt narxi. Valyuta: USD
52.88
+0.30 (0.57%)
Yopilishda: May 12, 2026, 4:00 PM EDT
BioMarin Pharmaceutical Inc., biotexnologiya kompaniyasi, Qo'shma Shtatlar, Yevropa, Lotin Amerikasi, Yaqin Sharq, Osiyo-Tinch okeani mintaqasi va xalqaro miqyosda hayot uchun xavfli noyob kasalliklar va tibbiy holatlar uchun terapiyalarni ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. Kompaniyaning mahsulotlari VIMIZIM, mukopolisakkaridoz (MPS) IV tip A, lizosomal saqlash buzilishini davolash uchun ferment o'rnini bosuvchi terapiya; VOXZOGO, axondroplaziyani davolash uchun kuniga bir marta in'ektsiya qilinadigan c-tipi natriuretik peptid (CNP) analogi; NAGLAZYME, MPS VI bilan og'rigan bemorlar uchun N-asetilgalaktozamin 4-sulfatazaning rekombinant shakli; va PALYNZIQ, qondagi Phe konsentratsiyasini kamaytirish uchun teri ostiga yuboriladigan PEGylated rekombinant fenilalanin (Phe) ammiakli liyaza fermentini o'z ichiga oladi. Shuningdek, kompaniya Batten kasalligining bir turi bo'lgan 2-toifali serebroid lipofusinozni davolash uchun rekombinant inson tripeptidil peptidaza 1 bo'lgan BRINEURA; inson fermenti alfa-L-iduronidazaning tabiiy shakliga o'xshash tozalangan protein bo'lgan ALDURAZYME; va irsiy metabolik kasallik bo'lgan fenilketonuriyali bemorlarni davolash uchun ishlatiladigan 6R-BH4 ning maxsus sintetik og'iz orqali qabul qilinadigan shakli bo'lgan KUVANni ishlab chiqadi. Kompaniyaning ishlab chiqilayotgan mahsulotlari axondroplaziya va gipoxondroplaziya kabi ko'plab o'sish buzilishlarini davolash uchun uzoqroq ta'sir qiluvchi CNP bo'lgan BMN 333; va duchenne mushak distrofiyasini davolash uchun o'ziga xos oligonucleotide bo'lgan BMN 351ni o'z ichiga oladi. Kompaniya ixtisoslashtirilgan dorixonalar, shifoxonalar, AQShdan tashqari davlat muassasalari, distribyutorlar va farmatsevtika ulgurji savdogarlariga xizmat ko'rsatadi. Kompaniya Ares Trading S.A. bilan litsenziya va hamkorlik shartnomalariga ega. Kompaniya 1996 yilda ro'yxatga olingan va San-Rafael, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. C. Greg Guyer Ph.D. | Executive VP & CTO |
| Dr. Gregory Friberg M.D. | Executive VP and Chief Research & Development Officer |
| Dr. Kevin Eggan Ph.D. | Chief Scientific Officer & Senior VP of Research and Early Development |
| Mr. Alexander Hardy | President, CEO & Director |
| Mr. Arpit Dave | Executive Vice President, Chief Digital & Information Officer |
| Mr. Brian R. Mueller CPA | CFO & Executive VP of Finance |
| Mr. George Eric Davis J.D. | Executive VP, Chief Legal Officer & Secretary |
| Ms. Amy Wireman | Executive VP & Chief People Officer |
| Ms. Cristin Hubbard | Executive VP & Chief Commercial Officer |
| Ms. Rashmi Eshwar Ramchandani | VP, Chief Accounting Officer & Principal Accounting Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-05 | 10-Q | bmrn-20260331.htm |
| 2026-05-04 | 8-K | bmrn-20260504.htm |
| 2026-04-27 | 8-K | d113922d8k.htm |
| 2026-04-23 | 8-K | d139584d8k.htm |
| 2026-04-21 | DEFA14A | a2026biomarinna.htm |
| 2026-03-16 | 8-K | d114815d8k.htm |
| 2026-02-26 | 10-K | bmrn-20251231.htm |
| 2026-02-23 | 8-K | bmrn-20260223.htm |
| 2026-02-12 | 8-K | d63881d8k.htm |
| 2026-01-29 | 8-K | d170996d8k.htm |